Oral @entity1855 fails to prevent XXXX following coronary artery surgery.

@entity1 @entity5032 @entity407 @entity1855 @entity591 @entity956 @entity955 @entity4710
A prospective randomised trial was performed on 100 @entity1 undergoing coronary artery bypass grafting without concomitant procedure. The study group commenced oral @entity1855 40 mg three times daily on the first post-operative day while the control group received no antiarrhythmic agents. The pre-operative characteristics of both groups were similar with the exception of the incidence of @entity407 which was greater in the @entity1855 group (P = 0.04). Myocardial protection was achieved with @entity5032 . Cardiopulmonary bypass times, aortic cross clamp times and graft numbers were similar for both groups. Nine @entity1 were excluded on the first post-operative day; the remainder were studied for 8 days. @entity4710 ( @entity955 , @entity956 or paroxysmal @entity4710 ) were detected in 8 @entity1 in the study group (n = 44) and in 5 @entity1 in the control group (n = 47). The difference was not significant (P = 0.3). The ventricular rate in @entity1 taking @entity1855 who developed @entity4710 was 138 +/- 14.9 compared with 156.8 +/- 17.9 in the control group, but the difference failed to reach significant levels (P = 0.065). In conclusion, prophylactic oral @entity1855 40 mg given three times daily after coronary artery surgery failed to decrease the incidence of post-operative @entity4710 or to significantly influence the ventricular rate if @entity591 developed.
